NWNico M. Wulffraat

Nico M. Wulffraat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nico M. Wulffraat has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 13 May 2010
      • Vol. 28  (2) , 281-6

    Transition of rheumatologic care, from teenager to adult: which health assessment questionnaire can be best used?

    by P A Van Pelt, A A Kruize, S S Goren, J Van Der Net, C S P Uiterwaal, W Kuis, J W J Bijlsma, N M Wulffraat

    Transition of care for adolescents includes a transfer from paediatric to adult health care. This requires a transfer of specific measurements, which evaluate disease profiles such as functional ability. One of the most common measurements is the Health Assessment Questionnaire (HAQ). Results of the Childhood HAQ (CHAQ) and HAQ were compared among adolescents diagnosed with rheumatic diseases involving the musculoskeletal system. All adolescents had recently dealt with or would in the near future be dealing with transition. Overall results of both questionnaires were comparable; intra-class correlation for consistency (ICC) was 0.95 (95% confidence interval 0.93-0.97). For a smooth transfer from CHAQ to HAQ, both correlation and agreement are required. Agreement between both questionnaires was not found. Described by limits of agreement, results of HAQ can differ from CHAQ as much as 0.95. Despite strong correlations for consistency, lack of agreement was found in the results of CHAQ and HAQ. If correlation persists over time, this study suggests evaluating both the childhood and adult version of the HAQ during the transition period. When transfer into adulthood is completed, comparison to earlier tests at younger age is available and reliable.


    • 21 June 2008
      • Vol. 26  (2) , 367-72

    The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate?

    by J K Reininga, L I Los, N M Wulffraat, W Armbrust

    The aims of this study are to examine in our juvenile idiopathic arthritis (JIA) population: 1) the prevalence and characteristics of uveitis, 2) the complications and outcome of uveitis, 3) prognostic factors, and 4) the adequacy of the current ophthalmologic screening guidelines. Retrospective analysis of medical records. 1) Of the 153 JIA patients included, 27 developed asymptomatic anterior uveitis (17.6%) - 7 unilateral and 20 bilateral. The 27 uveitis patients were significantly younger at JIA presentation than the 126 JIA patients without uveitis. 2) The following uveitis complications were noticed: glaucoma, cataract, posterior synechiae, cystoid macular oedema and papillitis. A visual outcome was acquired in 25 patients - 21 patients had a known visual acuity of > or = 0.1. Four patients had a visual acuity of <0.05 - 3 unilateral and 1 bilateral. 3) Female gender could not be confirmed as an independent risk factor for uveitis, neither was Anti Nuclear Antibody (ANA) positivity. We did not find a significant relationship between the moment of clinical remission of arthritis and of uveitis. 4) When applying current uveitis screening guidelines to our JIA population, we found that the optimum screening regimen would consist of a combination of the higher screening frequency of Southwood (1) and the longer screening period of the American Academy of Pediatrics (2) (AAP) screening guidelines. Uveitis is often encountered in JIA patients. It is a serious cause of morbidity. The use of disease-modifying antirheumatic drugs (DMARDs) probably has a positive effect on the preservation of visual function. We recommend a uveitis screening regimen which combines the AAP and Southwood guidelines and which includes rheumatoid factor positivity (RF+) and systemic onset patients in the quarterly screening.


    • 17 July 2007
      • Vol. 25  (3) , 480-5

    Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study.

    by A Van Der Meer, N M Wulffraat, B J Prakken, B Gijsbers, C M A Rademaker, G Sinnema

    To document the psychological side effects of methotrexate (MTX) treatment in children with juvenile idiopathic arthritis (JIA) and to explore the usefulness of psychological therapy to ameliorate these side effects. The patients included in this study consisted of 29 patients with JIA using MTX. Of these, ten were referred to a pediatric psychologist because of MTX side effects, and had behavioural therapy to cope with these side effects with a strong behavioural component (anticipatory nausea, anxiety). The behavioural therapy was adapted to age and used systemic desensitization (distraction in a positive atmosphere) or cognitive behavioural therapy (relaxation and overruling negative thoughts by positive ones). The parents of the 29 children were interviewed about MTX treatment and the side effects their child had developed. Parents of children referred to the psychologist were also interviewed for their impression of the results of the behavioural therapy. Prior to the behavioural therapy, nine out of 10 children reported MTX related nausea. Six of these ten were nauseous even before the administration and developed anticipatory nausea. Nine out of ten patients also showed some sign of distress in anticipation of MTX treatment, either orally of via injections. The behavioural therapy they had fully abolished side effects in five children and decreased the severity of nausea and distress in two children. Of the remaining nineteen children, not referred to the pediatric psychologist, 11 reported nausea after MTX treatment and four of these developed anticipatory nausea. In addition, eight of these 18 developed behavioural distress in anticipation of the treatment. This study showed that children with JIA who receive MTX treatment frequently develop psychological side effects, such as anticipatory nausea and behavioural distress in anticipation of treatment. This is true for patients selected for reported MTX side effects, as well as for randomly chosen JIA patients using MTX. As MTX is still the first choice in the treatment of severe JIA, more attention should be given to the treatment and prevention of side effects. Psychological intervention can be of help, but further studies are needed on the nature of the side effects, as well as on the prerequisites and efficacy of behavioural therapy.


  • Open Access

    Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005

    by Alan Tyndall, Ulrich A Walker, Andrew Cope, Francesco Dazzi, Cosimo De Bari, Willem Fibbe, Serena Guiducci, Simon Jones, Christian Jorgensen, Katarina Le Blanc, et al.

    Multipotent mesenchymal stromal cells isolated from bone marrow and other sites are currently being studied to determine their potential role in the pathogenesis and/or management of autoimmune diseases. In vitro studies have shown that they exhibit a dose-dependent antiproliferative effect on T and B lymphocytes, dendritic cells, natural killer cells and various B cell tumour lines – an effect that is both cell contact and soluble factor dependent. Animal models of autoimmune disease treated with multipotent mesenchymal stromal cells have mostly exhibited a positive clinical response, as have a limited number of patients suffering from acute graft versus host disease. This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts.


  • Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis

    by N M Wulffraat, B Vastert, A Tyndall

    Autologous stem cell transplantation (ASCT) can be performed in a variety of refractory autoimmune diseases. A retrospective multicenter analysis is presented to evaluate safety and efficacy of ASCT for refractory juvenile idiopathic arthritis. In all, 18 of the 34 patients (53%) with a follow-up of 12 to 60 months achieved a drug-free complete remission. There were three cases (9%) of transplant-related mortality and two cases of disease-related mortality (6%). Infectious complications were seen frequently. We propose adjustments in future protocols to reduce this mortality in this high-risk patient group.


  • Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective

    by R. E. Hough, J. A. Snowden, N. M. Wulffraat

    Summary: The potential of haemopoietic stem cell transplantation (HSCT) for the treatment of autoimmune and inflammatory diseases was originally supported by almost three decades of animal experiments and by the serindipitous remissions of autoimmune disease observed in patients undergoing transplantation for haematological disorders. Improved safety of both autologous and allogeneic HSCT over the last decade has been followed by increasing acceptance of HSCT as an experimental treatment for severe autoimmune diseases that are resistant to conventional treatment. International databases have collated over 700 procedures performed specifically for a variety of autoimmune diseases. Phase III clinical trials are in progress for some diseases. This review provides a comprehensive update on the efficacy and toxicity of HSCT in severe autoimmune disease. Future directions in the context of other evolving therapies are discussed.


  • Open Access

    Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity

    by I M de Kleer, D M C Brinkman, A Ferster, M Abinun, P Quartier, J van der Net, R Ten Cate, L R Wedderburn, G Horneff, J Oppermann, et al.

    Objective: To evaluate the safety and efficacy of autologous stem cell transplantation (ASCT) for refractory juvenile idiopathic arthritis (JIA). Design: Retrospective analysis of follow up data on 34 children with JIA who were treated with ASCT in nine different European transplant centres. Rheumatological evaluation employed a modified set of core criteria. Immunological reconstitution and infectious complications were monitored at three month intervals after transplantation. Results: Clinical follow up ranged from 12 to 60 months. Eighteen of the 34 patients (53%) with a follow up of 12 to 60 months achieved complete drug-free remission. Seven of these patients had previously failed treatment with anti-TNF. Six of the 34 patients (18%) showed a partial response (ranging from 30% to 70% improvement) and seven (21%) were resistant to ASCT. Infectious complications were common. There were three cases of transplant related mortality (9%) and two of disease related mortality (6%). Conclusions: ASCT in severely ill patients with JIA induces a drug-free remission of the disease and a profound increase in general wellbeing in a substantial proportion of patients, but the procedure carries a significant mortality risk. The following adjustments are proposed for future protocols: (1) elimination of total body irradiation from the conditioning regimen; (2) prophylactic administration of antiviral drugs and intravenous immunoglobulins until there is a normal CD4+ T cell count.


  • Refractory juvenile idiopathic arthritis

    by Nico M Wulffraat, Ismee M de Kleer, Berent J Prakken, Wietse Kuis


    • 16 April 2004
      • Vol. 22  (2) , 252-8

    Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.

    by L Dekker, W Armbrust, C M A Rademaker, B Prakken, W Kuis, N M Wulffraat

    Anti-TNFalpha agents are frequently used in the treatment of severe JIA. Etanercept, a fully human soluble recombinant tumour necrosis factor p75 receptor Fc fusion protein, has been registered for the treatment of polyarticular course JIA patients who fail to respond to or do not tolerate methotrexate (MTX). Infliximab, a chimeric human-mouse monoclonal antibody to TNFalpha, is expected to be registered soon for JIA and Crohn's disease (CD) in children. As in adults, both agents are effective in controlling inflammation and inhibiting the progression of joint destruction. Despite this good clinical efficacy, the physician must remain alert for potential side effects, especially after prolonged use. This review gives an overview of the reported adverse events.


  • Open Access

    Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis

    by W. Armbrust, S. S. M. Kamphuis, T. W. F. Wolfs, T. J. W. Fiselier, P. G. Nikkels, W. Kuis, N. M. Wulffraat

    Sir, A 5-yr-old girl presented in 1998 with typical features of systemic juvenile idiopathic arthritis (s-JIA). Remission was difficult to accomplish despite the use of steroids and indomethacin. Because of a polyarticular course and multiple relapses of fever, high-dose methotrexate (MTX), cyclosporin and recurrent methyl prednisone pulses were administered. In 2000 she developed severe, persistent lymphopenia and decreased in vitro cellular responses to mitogens, antigens and purified protein derivate (PPD). This was probably caused by the prolonged use of immunosupressive medication. Because of persistent disease activity and steroid dependency, etanercept (0.4 mg/kg twice a week) was added in 2001 to the MTX and prednisone. Cyclosporin was stopped. Increasing the dose to 0.8 mg/kg twice a week did not have any effect on the arthritis. Etanercept was stopped and high-dose infliximab (20 mg/kg/month) was added in January 2002 [1]. Fever changed from a spiking pattern to a more continuous pattern and arthritis persisted. Infliximab was stopped. Recurrent extensive microbiological screening did not reveal pathogenic micro-organisms. Bronchoalveolar lavage was negative for pathogens, including Mycobacterium tuberculosis. Given the resistant nature of her s-JIA, the girl was evaluated for possible autologous stem-cell transplantation. During this evaluation she developed a cystic subcutaneous swelling at the left wrist which had no clear connection to the joint. MRI showed a cystic process without signs of osteomyelitis. The fluid of the cyst was aspirated. PCR was positive for M. tuberculosis. Culture was negative. Cultures and PCR of cerebrospinal fluid, fasting stomach contents, bone marrow aspirate and blood for M. tuberculosis remained negative. Because she had an extrapulmonary lesion in the presence of a chronic immunodeficient state, tuberculostatic therapy with ethambutol, isoniazid, pyrazinamide and rifampicin was started. One month later a central venous line was removed. Within an hour after general anaesthesia she developed acute respiratory insufficiency and cardiac arrest. After resuscitation, high-pressure ventilatory support was needed. Saturation remained low (65%), with high central venous pressure. Under the suspicion of a pulmonary embolism, anticoagulation therapy was started. A few hours later she died due to respiratory and circulatory failure. On autopsy no pulmonary embolism could be diagnosed. Macroscopically, the lungs showed a fine granular aspect on the cut surface. Microscopy revealed a massive lipid pneumonia with fulminant alveolar damage and an infiltrate of neutrophils and macrophages (Fig. 1). Hardly any normal lung tissue was seen. A chronic (opportunistic) infection on the basis of these findings was strongly suspected. Auramin and Ziehl-Neelsen preparations were negative, however, as were PCR tests for M. tuberculosis on the lung tissue and pleural fluid. Therefore, the diagnosis of pulmonary tuberculosis could not be confirmed. Culture of the catheter tip was positive for Escherichia coli. Cultures for specific mycobacterial species, atypical pathogens and opportunistic agents were also negative. Bacterial cultures showed E. coli and Enterobacter species.